LT3560498T - Derinys apimantis mek inhibitorių ir b-raf inhibitorių - Google Patents

Derinys apimantis mek inhibitorių ir b-raf inhibitorių

Info

Publication number
LT3560498T
LT3560498T LTEP19174594.2T LT19174594T LT3560498T LT 3560498 T LT3560498 T LT 3560498T LT 19174594 T LT19174594 T LT 19174594T LT 3560498 T LT3560498 T LT 3560498T
Authority
LT
Lithuania
Prior art keywords
inhibitor
combination
raf
mek
mek inhibitor
Prior art date
Application number
LTEP19174594.2T
Other languages
English (en)
Inventor
Melissa Dumble
Rakesh Kumar
Sylvie Laquerre
Peter Lebowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3560498(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3560498T publication Critical patent/LT3560498T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
LTEP19174594.2T 2009-10-16 2010-10-15 Derinys apimantis mek inhibitorių ir b-raf inhibitorių LT3560498T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16

Publications (1)

Publication Number Publication Date
LT3560498T true LT3560498T (lt) 2022-11-25

Family

ID=43876568

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP10824148.0T LT2488033T (lt) 2009-10-16 2010-10-15 Derinys, apimantis mek inhibitorių ir b-raf inhibitorių
LTEP19174594.2T LT3560498T (lt) 2009-10-16 2010-10-15 Derinys apimantis mek inhibitorių ir b-raf inhibitorių

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP10824148.0T LT2488033T (lt) 2009-10-16 2010-10-15 Derinys, apimantis mek inhibitorių ir b-raf inhibitorių

Country Status (33)

Country Link
US (3) US8703781B2 (lt)
EP (3) EP3560498B1 (lt)
JP (1) JP5718929B2 (lt)
KR (1) KR101729116B1 (lt)
CN (1) CN102655753B (lt)
AU (1) AU2010306653B2 (lt)
BR (1) BR112012008854B8 (lt)
CA (1) CA2775803C (lt)
CL (1) CL2012000964A1 (lt)
CO (1) CO6531498A2 (lt)
CR (1) CR20120155A (lt)
CY (1) CY1122013T1 (lt)
DK (2) DK3560498T3 (lt)
DO (1) DOP2012000091A (lt)
EA (1) EA020589B1 (lt)
ES (2) ES2745479T3 (lt)
HR (2) HRP20221304T1 (lt)
HU (2) HUE046139T2 (lt)
IL (1) IL219073A (lt)
LT (2) LT2488033T (lt)
MA (1) MA33746B1 (lt)
ME (1) ME03497B (lt)
MX (1) MX2012004413A (lt)
MY (1) MY174759A (lt)
NZ (1) NZ598913A (lt)
PE (1) PE20121093A1 (lt)
PL (2) PL2488033T3 (lt)
PT (2) PT3560498T (lt)
RS (2) RS63702B1 (lt)
SI (1) SI2488033T1 (lt)
UA (1) UA105064C2 (lt)
WO (1) WO2011047238A1 (lt)
ZA (1) ZA201202612B (lt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201903981T4 (tr) 2008-06-16 2019-04-22 Univ Ohio State Res Found Kanser tedavisi için bileşikler.
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
AU2012358999A1 (en) * 2011-12-22 2014-07-10 Glaxosmithkline Llc Method of treating cancer with MAGEA3 immunotherapeutic with BRAF inhibitor and/or MEK inhibitor
US20150126533A1 (en) * 2012-03-30 2015-05-07 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
CA2882437C (en) * 2012-09-04 2021-03-02 Glaxosmithkline Llc Method of adjuvant cancer treatment
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
MA38121A1 (fr) * 2012-11-30 2016-10-31 Glaxosmithkline Llc Nouvelle composition pharmaceutique
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
JP6835472B2 (ja) * 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
SG11201509742QA (en) * 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2015003571A1 (zh) * 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
US20160367662A1 (en) * 2013-12-12 2016-12-22 Novartis Ag Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
EP3524694B1 (en) 2013-12-28 2020-07-15 Guardant Health, Inc. Methods and systems for detecting genetic variants
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
EP3139919B1 (en) 2014-05-06 2020-06-03 Oncternal Therapeutics, Inc Compounds for treatment of cancer
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
JP2019537604A (ja) * 2016-11-03 2019-12-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｅｇｆｒ／ｐｉ３ｋの小分子二重阻害剤及びその使用
CN112867803A (zh) 2018-10-16 2021-05-28 诺华股份有限公司 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220142979A1 (en) * 2019-07-26 2022-05-12 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN114981298A (zh) 2019-12-12 2022-08-30 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
WO2023081676A1 (en) * 2021-11-02 2023-05-11 Verastem, Inc. Methods of treating abnormal cell growth
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1233769B1 (en) 1999-11-22 2007-12-26 SmithKline Beecham plc Imidazole derivatives
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
RS52670B (en) 2004-06-11 2013-06-28 Japan Tobacco Inc. 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
JP5479337B2 (ja) * 2007-07-30 2014-04-23 アルディア バイオサイエンス，インク． Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
LT2488033T (lt) 2019-09-10
AU2010306653A1 (en) 2012-05-10
BR112012008854B8 (pt) 2021-05-25
EP2488033B1 (en) 2019-06-12
MA33746B1 (fr) 2012-11-01
CY1122013T1 (el) 2020-10-14
DK2488033T3 (da) 2019-09-02
DK3560498T3 (da) 2022-11-14
AU2010306653B2 (en) 2013-10-24
PL3560498T3 (pl) 2022-12-12
EA020589B1 (ru) 2014-12-30
CN102655753A (zh) 2012-09-05
BR112012008854A2 (pt) 2015-09-22
WO2011047238A1 (en) 2011-04-21
RS63702B1 (sr) 2022-11-30
JP2013508294A (ja) 2013-03-07
IL219073A0 (en) 2012-06-28
US20140187566A1 (en) 2014-07-03
US20120196879A1 (en) 2012-08-02
EA201290149A1 (ru) 2012-11-30
IL219073A (en) 2016-05-31
UA105064C2 (uk) 2014-04-10
CL2012000964A1 (es) 2012-08-31
CA2775803A1 (en) 2011-04-21
HRP20191617T1 (hr) 2019-12-13
HUE060206T2 (hu) 2023-02-28
EP4159217A1 (en) 2023-04-05
RS59181B1 (sr) 2019-10-31
ZA201202612B (en) 2013-09-25
ES2930157T3 (es) 2022-12-07
US20150111904A1 (en) 2015-04-23
MX2012004413A (es) 2012-05-08
ME03497B (me) 2020-04-20
CO6531498A2 (es) 2012-09-28
KR20120104547A (ko) 2012-09-21
EP3560498B1 (en) 2022-08-17
EP2488033A1 (en) 2012-08-22
PL2488033T3 (pl) 2019-12-31
HUE046139T2 (hu) 2020-02-28
MY174759A (en) 2020-05-13
EP2488033A4 (en) 2014-04-30
CA2775803C (en) 2017-11-21
PT3560498T (pt) 2022-11-03
DOP2012000091A (es) 2013-09-15
SI2488033T1 (sl) 2019-10-30
CR20120155A (es) 2012-07-05
BR112012008854B1 (pt) 2020-12-29
CN102655753B (zh) 2015-11-25
KR101729116B1 (ko) 2017-05-02
PT2488033T (pt) 2019-09-10
JP5718929B2 (ja) 2015-05-13
PE20121093A1 (es) 2012-09-04
HRP20221304T1 (hr) 2022-12-23
ES2745479T3 (es) 2020-03-02
NZ598913A (en) 2013-11-29
US8952018B2 (en) 2015-02-10
US8703781B2 (en) 2014-04-22
EP3560498A1 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
PL2488033T3 (pl) Kombinacja zawierająca inhibitor MEK i inhibitor B-raf
ZA201202618B (en) Combinations of a p13k inhibitor and a mek inhibitor
PL2328784T3 (pl) Połączenie ramienia wycieraczki z piórem wycieraczki oraz pióro wycieraczki
ZA201204700B (en) Optimized endonucleases and uses thereof
IL214403A0 (en) Novelcell lines and methods
EP2443259A4 (en) BIOMARKERS FOR AUTISM AND USES THEREOF
GB2469720B (en) Join-us call-log and call-answer messages
EP2429624A4 (en) EXPANDABLE DEVICES AND METHOD THEREFOR
EP2441383A4 (en) DEVICE AND METHOD FOR DETERMINING AN OBJECT TO BE FIXED
EP2490077A4 (en) ELECTRIFICATION ELEMENT AND ELECTROPHOTOGRAPHIC DEVICE
IL217761A0 (en) Dilator and assembly comprising such a dilator
EP2517684A4 (en) AIRWAY OPENING TOOL AND AIRWAY OPENING UNIT THEREWITH
HK1176997A1 (en) Labeling and authenticating using a microtag
HK1174435A1 (zh) 磁性部件和電子元件
EP2399993A4 (en) STREPTAVIDINE HYPO-IMMUNOGEN AND USE THEREOF
GB0908280D0 (en) Trackbed liner and related methods
GB2473864B (en) Improved mouthguard and tool
EP2419091A4 (en) NANOCANAL DEVICE AND RELATED METHODS
GB0912744D0 (en) Methods and uses
GB0909380D0 (en) Method and use
EP2443622A4 (en) CURRENT CONTROLLED PIXEL CIRCUITS AND ASSOCIATED METHODS
TWM374132U (en) Hard disk fixing device and electronic device
EP2291396A4 (en) MODIFIED GALECTIN-2 AND USES THEREOF
GB0916070D0 (en) Power and data unit
IL216594A0 (en) Proteasome inhibitors and uses thereof